SCHEMBL21687487

SCHEMBL21687487

N#Cc1ccc2c(c1)c1cc(C#N)ccc1n2-c1cccc(-c2c(C#N)cccc2[Si](c2ccccc2)(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
TDP2 O95551 3/20 0.34
TSHR P16473 2/20 0.34
GRM5 P41594 2/20 0.33
G6PD P11413 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
TP53 P04637 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HIF1A Q16665 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21687689 0.97 KDM4E (0.34) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21687665 0.91 RARG (0.33) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21687470 0.90 SMN1; SMN2 (0.34) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21687973 0.90 KDM4E (0.39) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21687994 0.89 SMN1; SMN2 (0.34) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21687873 0.89 CYP1A2 (0.32) LMNASMN1; SMN2ALDH1A1MAPK1TSHR
SCHEMBL21688016 0.89 KDM4E (0.34) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21688047 0.88 KDM4E (0.33) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21688197 0.87 ALDH1A1 (0.38) LMNASMN1; SMN2ALDH1A1HPGDMAPK1
SCHEMBL21688199 0.87 ALDH1A1 (0.35) LMNASMN1; SMN2ALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-12-14 US disclosed
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND CRY1, CCNL2, CCNE2 LMNA 1582/4885SMN1; SMN2 4039/4885ALDH1A1 616/4885
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound CRY1, CCNL2, CCNE2 LMNA 1582/4885SMN1; SMN2 4039/4885ALDH1A1 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.